TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37587595

Group type: EXPERIMENTAL
Intervention: CA-AKI risk score model 1
Number of subjects: 8201

Group type: EXPERIMENTAL
Intervention: CA-AKI risk score model 2
Number of subjects: 8201

Group type: EXPERIMENTAL
Intervention: CA-AKI patients
Number of subjects: 8201
Study: 37587606

Group type: EXPERIMENTAL
Intervention: Pacemaker Implantation after TAVR
Number of subjects: 0
Study: 37587734

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective supraclavicular nerve block with 0.1 mL/kg of 0.5% ropivacaine (SSCNB group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective supraclavicular nerve block
Number of subjects: 50
Study: 37587845

Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 805
Study: 37588049

Group type: EXPERIMENTAL
Intervention: Kombucha tea
Number of subjects: 0
Study: 37588173

Group type: EXPERIMENTAL
Intervention: Inspired oxygen fraction of 0.8 (hyperoxia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inspired oxygen fraction of 0.3 (normoxaemia)
Number of subjects: 0
Study: 37588266

Group type: EXPERIMENTAL
Intervention: Weight-adjusted dosing of fibrinogen concentrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Empiric dosing of fibrinogen concentrate
Number of subjects: 0
Study: 37588271

Group type: EXPERIMENTAL
Intervention: Increased IL-8 on postoperative day 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased IL-10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 0
Study: 37588575

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 5
Study: 37588584

Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with propofol and alfentanil
Number of subjects: 40
Study: 37588582

Group type: EXPERIMENTAL
Intervention: In-hospital postoperative complications of any cause
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-hospital all-cause mortality
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration of hospital stay after surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Admission to a critical care unit within 30 days after surgery during the index hospitalisation
Number of subjects: 0
Study: 37588667

Group type: EXPERIMENTAL
Intervention: Daily electronically recorded patient-reported outcomes (ePROs) on the presence of MG symptoms, level of symptom severity (MG-ADL), and exacerbation status.
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Self-reported MG-ADL scores during exacerbation periods.
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Self-reported MG-ADL scores during non-exacerbation periods.
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Dynamic changes in day-to-day symptom reporting and severity, daily step counts, clinical characteristics.
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Unsupervised machine learning methods applied to symptom data.
Number of subjects: 113
Study: 37588691

Group type: EXPERIMENTAL
Intervention: Altered cerebral autoregulation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Preserved cerebral autoregulation
Number of subjects: 36
Study: 37588731

Group type: EXPERIMENTAL
Intervention: IORT boost with low kV X-rays
Number of subjects: 73
Study: 37588783

Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvres in the prone position
Number of subjects: 30
Study: 37588787

Group type: EXPERIMENTAL
Intervention: Lower oxygenation target (8 kPa)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Higher oxygenation target (12 kPa)
Number of subjects: 168
Study: 37588789

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study: 37589154

Group type: EXPERIMENTAL
Intervention: Intensive SBP intervention (<120 mm Hg)
Number of subjects: 7939

Group type: COMPARATOR
Intervention: Standard SBP intervention (<140 mm Hg)
Number of subjects: 7939
Study: 37589161

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation (CCRT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 48
Study: 37589219

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study: 37589315

Group type: EXPERIMENTAL
Intervention: Post-ICU stroke
Number of subjects: 3144

Group type: EXPERIMENTAL
Intervention: Post-ICU depression
Number of subjects: 3144
Study: 37589506

Group type: EXPERIMENTAL
Intervention: TNFR2 small interfering RNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control treatment
Number of subjects: 0
Study: 37589641

Group type: EXPERIMENTAL
Intervention: Multiphase SCS therapy A (approximately 600-1500 Hz)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Multiphase SCS therapy B (approximately 300-600 Hz)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Commercial SCS therapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Multiphase SCS
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 122
Study: 37589639

Group type: EXPERIMENTAL
Intervention: Autologous IFNγ-stimulated MSC(M) injection into submandibular gland
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Autologous IFNγ-stimulated MSC(M) injection
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Quality of life surveys
Number of subjects: 6
Study: 37589642

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex targeting the painful limb, administered over five months
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex targeting the painful limb
Number of subjects: 11
Study: 37589719

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Controls with overweight/obesity (CWO)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Controls with overweight/obesity (CWO) and Type 2 diabetes (T2D)
Number of subjects: 76
Study: 37589748

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: MAD therapy
Number of subjects: 31
Study: 37589906

Group type: EXPERIMENTAL
Intervention: Reporting break
Number of subjects: 45

Group type: COMPARATOR
Intervention: No reporting break
Number of subjects: 45
Study: 37589932

Group type: EXPERIMENTAL
Intervention: IPL + DQS therapy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IPL therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 66
Study: 37589975

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard educational packet (Control)
Number of subjects: 95
Study: 37589978

Group type: EXPERIMENTAL
Intervention: Mediterranean nutrition intervention (access to supermarket discounts, free samples of Mediterranean diet foods, online nutrition education, email reminders, family and peer support, chef demonstrations)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Mediterranean nutrition intervention
Number of subjects: 485

Group type: COMPARATOR
Intervention: Control (usual diet)
Number of subjects: 485
Study: 37590001

Group type: EXPERIMENTAL
Intervention: Anticancer agents targeting AMPK
Number of subjects: 0
Study: 37590002

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Watchful Waiting with Supportive Care (WWSC)
Number of subjects: 386
Study: 37590017

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37590203

Group type: EXPERIMENTAL
Intervention: Continuous vibrating mesh nebuliser
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intermittent vibrating mesh nebuliser
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent jet nebuliser
Number of subjects: 60
Study: 37590267

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CCTA) performed once at the beginning of the study.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Echocardiography with GLS assessment performed every three months during follow-up.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Measurement of new biomarkers of atherosclerosis (IL-6, MPO, TNF-alpha) every 6 months.
Number of subjects: 80
Study: 37590355

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37591034

Group type: EXPERIMENTAL
Intervention: Testosterone quartile 1
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Oestrone quartile 1
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Testosterone quartile 1 (expanded definition)
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Oestrone quartile 1 (expanded definition)
Number of subjects: 5535

Group type: EXPERIMENTAL
Intervention: Low DHEA (expanded definition)
Number of subjects: 5535
Study: 37591042

Group type: EXPERIMENTAL
Intervention: Family Promoting Positive Emotions (FPPE)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Written Information (WI)
Number of subjects: 74
Study: 37591292

Group type: EXPERIMENTAL
Intervention: Nefecon (targeted-release formulation of budesonide)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study: 37591293

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks for up to 108 weeks
Number of subjects: 712

Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Cemiplimab plus chemotherapy (as second-line therapy)
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks
Number of subjects: 712
Study: 37591308

Group type: EXPERIMENTAL
Intervention: Interventional clinical trials for Becker muscular dystrophy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural history studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment concepts converting DMD to BMD phenotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaborative efforts to improve trial readiness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broad spectrum of disease severity
Number of subjects: 0
Study: 37591454

Group type: EXPERIMENTAL
Intervention: 5 new VAD item banks/measures developed: 6-item VAD Team Communication
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 12-item Self-efficacy Regarding VAD Self-care
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 11-item Being Bothered by VAD Self-care and Limitations
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 7-item Satisfaction with Treatment
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: 11-item Stigma
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: All measures except VAD Team Communication
Number of subjects: 620
Study: 37591480

Group type: EXPERIMENTAL
Intervention: Black Veterans with a mental health diagnosis (n = 175)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Black Veterans without a mental health diagnosis (n = 205)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Racialized discrimination in health care
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Pain self-efficacy
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Pain-related fear avoidance beliefs
Number of subjects: 380
Study: 37591523

Group type: COMPARATOR
Intervention: Prophylactic anticoagulants
Number of subjects: 1777

Group type: COMPARATOR
Intervention: Higher-dose apixaban
Number of subjects: 1777

Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 1777
Study: 37591633

Group type: EXPERIMENTAL
Intervention: Tocilizumab (280 mg single dose)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study: 37591642

Group type: EXPERIMENTAL
Intervention: TruST-support intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Static trunk support intervention
Number of subjects: 82
Study: 37591648

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Demographics and outcomes of hospitalised patients with COVID-19
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Facility-level oxygen production and support
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Respiratory support transitions
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier models
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Multistate model
Number of subjects: 4500
Study: 37591655

Group type: EXPERIMENTAL
Intervention: 4.2% sodium bicarbonate infusion to target a plasma pH ≥ 7.30
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no sodium bicarbonate infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4.2% sodium bicarbonate infusion
Number of subjects: 0
Study: 37591656

Group type: EXPERIMENTAL
Intervention: Letrozole-stimulated protocol
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Hormone replacement treatment (HRT)
Number of subjects: 1078
Study: 37592020

Group type: EXPERIMENTAL
Intervention: WRAPSODY™ Cell-Impermeable Endoprosthesis
Number of subjects: 500
Study: 37592059

Group type: EXPERIMENTAL
Intervention: Maternal metabolomic profile during pregnancy (1st, 2nd, 3rd trimester)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Maternal metabolomic profile during pregnancy (2nd trimester)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Maternal metabolomic profile during pregnancy (3rd trimester)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Cord blood metabolomic profile
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Ascending early growth
Number of subjects: 572
Study: 37592092

Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg QD (step-in dosing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bosutinib 400 mg QD (approved first-line dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bosutinib 500 mg QD (approved later-line dose)
Number of subjects: 0
Study: 37592104

Group type: EXPERIMENTAL
Intervention: Combination of ipilimumab and nivolumab
Number of subjects: 92

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Change in intratumoral CD8 T cell density
Number of subjects: 92
Study: 37592106

Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel)
Number of subjects: 62
Study: 37592153

Group type: EXPERIMENTAL
Intervention: Expert panel grading of developmental milestones using home video recordings
Number of subjects: 5
Study: 37592166

Group type: EXPERIMENTAL
Intervention: PPV > 9.5%
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Controlled ventilation with low spontaneous effort
Number of subjects: 189
Study: 37592217

Group type: EXPERIMENTAL
Intervention: Intensive intervention targeting categorical perception, rapid automatized naming, and phonemic analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard speech therapy remediation
Number of subjects: 0
Study: 37592243

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD) (< 20 E% carbohydrates, 50-60 E% fat)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control diet (50-60 E% carbohydrates, 20-30 E% fat)
Number of subjects: 71
Study: 37592263

Group type: EXPERIMENTAL
Intervention: Inhalation technique errors 'Breathe in', 'Hold breath', 'Breathe out calmly after inhalation'
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Inhalation technique errors 'Preparation', 'Hold inhaler in correct position during inhalation', 'Breathe in'
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Overall inhalation technique errors
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Specific combinations of inhalation technique errors
Number of subjects: 1434

Group type: EXPERIMENTAL
Intervention: Increasing inhalation technique error count
Number of subjects: 1434
Study: 37592272

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1108
Study: 37592288

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 15
Study: 37592290

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 60
Study: 37592299

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical hysterectomy (RH)
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Abdominal radical hysterectomy (RH)
Number of subjects: 1104
Study: 37592303

Group type: EXPERIMENTAL
Intervention: High CLDN6 mRNA expression
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: CLDN6 protein expression
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Treatment-naïve subgroups and cohorts receiving neoadjuvant therapy
Number of subjects: 460
Study: 37592314

Group type: EXPERIMENTAL
Intervention: User-centred strategy (includes TB-education booklet, contact-identification algorithm, instructional sputum-collection video, community-health-rider service, collaborative improvement meetings, regular audit-and-feedback reports, digital group-chat application)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard strategy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: User-centred strategy
Number of subjects: 12
Study: 37592320

Group type: EXPERIMENTAL
Intervention: Pharmacological active placebo intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological active placebo intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural course control group
Number of subjects: 0
Study: 37592358

Group type: EXPERIMENTAL
Intervention: Music intervention (twice daily for three days, at least 30 min per session)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 94
Study: 37592359

Group type: EXPERIMENTAL
Intervention: Connect To Care (C2C) intervention delivered by a Care Coach via telephone and/or video, focusing on strengths-based approach with four components: identifying patient strengths, collaborative decision-making, resolving barriers to care, and monitoring progress.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 37592403

Group type: EXPERIMENTAL
Intervention: 2.5 mL of 40% ethanol per kg body weight via a nasogastric tube
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 38
Study: 37592860

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with language therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Language treatment alone (Control)
Number of subjects: 0
Study: 37592858

Group type: EXPERIMENTAL
Intervention: γδ T cell-based immunotherapeutic strategies; specific dosage and duration not available
Number of subjects: 0
Study: 37593110

Group type: EXPERIMENTAL
Intervention: Hybrid comprehensive telerehabilitation (HCTR)
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Usual rehabilitation care
Number of subjects: 1578
Study: 37593221

Group type: EXPERIMENTAL
Intervention: sintilimab plus bevacizumab (200 mg and 7.5 mg/kg respectively, intravenously every 3 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: sintilimab plus bevacizumab
Number of subjects: 33
Study: 37593224

Group type: EXPERIMENTAL
Intervention: Adult-onset T1D
Number of subjects: 218

Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Type 2 Diabetes (T2D)
Number of subjects: 218
Study: 37593227

Group type: EXPERIMENTAL
Intervention: AK112 combined with pemetrexed (500 mg/m2) in cohort 1 (previously untreated)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: AK112 combined with chemotherapy in cohort 2 (EGFR-functional mutation)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: AK112 combined with chemotherapy in cohort 3 (failed prior systemic treatments)
Number of subjects: 83
Study: 37593752

Group type: EXPERIMENTAL
Intervention: feladilimab (anti-ICOS mAb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: feladilimab (anti-ICOS mAb) + pembrolizumab (PD-1 inhibitor)
Number of subjects: 0
Study: 37593833

Group type: EXPERIMENTAL
Intervention: Diabetes self-management program led by registered nurses (RNs)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Diabetes self-management program led by community health workers
Number of subjects: 330
Study: 37593838

Group type: EXPERIMENTAL
Intervention: DWP16001 (2 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Phentermine (37.5 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of DWP16001 and phentermine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 37593881

Group type: EXPERIMENTAL
Intervention: Vimseltinib 30 mg twice weekly for up to 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (inactive substance) for up to 24 weeks
Number of subjects: 0
Study: 37594044

Group type: EXPERIMENTAL
Intervention: Mirikizumab 200 mg subcutaneous every 4 or 12 weeks through week 52
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 37594640

Group type: EXPERIMENTAL
Intervention: Palbociclib plus Letrozole
Number of subjects: 130
Study: 37594646

Group type: EXPERIMENTAL
Intervention: Ripple mapping-guided isthmus ablation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 200
Study: 37594667

Group type: EXPERIMENTAL
Intervention: Cancer stress
Number of subjects: 76

Group type: COMPARATOR
Intervention: COVID-19 stress
Number of subjects: 76
Study: 37594766

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37594769

Group type: COMPARATOR
Intervention: Algorithmic approach to ventilator withdrawal; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care for ventilator withdrawal; details on dosage and duration not available.
Number of subjects: 0
Study: 37594793

Group type: EXPERIMENTAL
Intervention: Wearable devices and AI (smartwatches collecting physiological data)
Number of subjects: 40
Study: 37594946

Group type: EXPERIMENTAL
Intervention: Play-based, parent-delivered intervention focusing on regaining pre-treatment mobility and midline crossing until 7 weeks post-treatment, individualized from 7 weeks to 6 months post-treatment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0